Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases

被引：6
|
作者：
Jiang, Tao [1 ,2 ]
Xu, Xiaobo [2 ]
Chen, Xiaojuan [3 ]
Ding, Ning [2 ]
Hu, Qin [4 ]
Zhou, Caicun [1 ]
Hu, Jie [2 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai Resp Res Inst, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[3] Wenzhou Med Univ, Dept Gastroenterol, Wenzhou Clin Inst 3, Wenzhou Peoples Hosp, Wenzhou, Peoples R China
[4] Fudan Univ, Shanghai Resp Res Inst, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 06期
基金：
中国国家自然科学基金;
关键词：
CELL LUNG-CANCER; ERLOTINIB; SURVIVAL;
D O I：
10.21037/tlcr-20-984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2514 / 2517
页数：4
相关论文
共 50 条
  • [21] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
    Ramalingam, S. S.
    Vansteenkiste, J.
    Planchard, D.
    Cho, B. C.
    Gray, J. E.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Cobo, M.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M-C
    Imamura, F.
    Kurata, T.
    Todd, A.
    Hodge, R.
    Saggese, M.
    Rukazenkov, Y.
    Soria, J-C
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
  • [22] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Lu, Shun
    Kato, Terufumi
    Dong, Xiaorong
    Ahn, Myung-Ju
    Quang, Le-Van
    Soparattanapaisarn, Nopadol
    Inoue, Takako
    Wang, Chih-Liang
    Huang, Meijuan
    Yang, James Chih-Hsin
    Cobo, Manuel
    Ozguroglu, Mustafa
    Casarini, Ignacio
    Khiem, Dang-Van
    Sriuranpong, Virote
    Cronemberger, Eduardo
    Takahashi, Toshiaki
    Runglodvatana, Yotsawaj
    Chen, Ming
    Huang, Xiangning
    Grainger, Ellie
    Ghiorghiu, Dana
    van der Gronde, Toon
    Ramalingam, Suresh S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [23] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Banna, Giuseppe Luigi
    Addeo, Alfredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1555 - 1556
  • [24] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [25] Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
    Zheng, M-M
    Lin, S-H
    Li, Y-S
    Yin, K.
    Li, P.
    Zhang, X-C
    Gao, S-X
    Zhou, Q.
    Tu, H-Y
    Yang, J-J
    Chen, H-J
    Pan, Y.
    Wang, B-C
    Wang, Z.
    Xu, C-R
    Xiao, F-M
    Zhong, W-Z
    Yan, H-H
    Tang, L-B
    Wu, L.
    Zeng, L.
    Liu, S-Y. M.
    Wong, C. C.
    Wu, Y-L
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S80 - S81
  • [26] Osimertinib for leptomeningeal metastases in NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2020, 21 (01): : E17 - E17
  • [27] Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
    Brouns, Anita J. W. M.
    van Veelen, Ard
    Veerman, G. D. Marijn
    Steendam, Christi
    Dursun, Safiye
    van der Leest, Cor
    Croes, Sander
    Dingemans, Anne-Marie C.
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
  • [28] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Masahiro Tsuboi
    Roy S. Herbst
    Thomas John
    Terufumi Kato
    Margarita Majem
    Christian Grohé
    Jie Wang
    Jonathan W. Goldman
    Shun Lu
    Filippo de Marinis
    Frances A. Shepherd
    Ki Hyeong Lee
    Nhieu Thi Le
    Arunee Dechaphunkul
    Dariusz Kowalski
    Laura Bonanno
    Manuel Dómine
    Lynne Poole
    Ana Bolanos
    Yuri Rukazenkov
    Yi-Long Wu
    Targeted Oncology, 2024, 19 : 131 - 134
  • [29] Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
    Gulikers, Judith L.
    Veerman, G. D. Marijn
    Jebbink, Merel
    Kruithof, Paul D.
    Steendam, Christi M. J.
    Boosman, Rene J.
    Mathijssen, Ron H. J.
    Tjan-Heijnen, Vivianne C. G.
    Driessen, Johanna H. M.
    Dursun, Safiye
    Smit, Egbert F.
    Dingemans, Anne -Marie C.
    van Geel, Robin M. J. M.
    Croes, Sander
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [30] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
12345